{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-022167","form_type":"8-K","ticker":"CORT","cik":"0001088856","company_name":"CORCEPT THERAPEUTICS INC","filed_at":"2025-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.471954+00:00","generated_at":"2026-05-22T16:23:34.144339+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Corcept Q1 revenue $157.2M (+7%); FY25 guide $900-950M reaffirmed; relacorilant & dazucorilant updates","bullets":["Revenue $157.2M, up 7% YoY; diluted EPS $0.17 vs $0.25; operating expenses rose to $153.8M from $117.3M.","Reiterated FY 2025 revenue guidance $900-950M; cash/investments $570.8M (down from $603.2M due to buybacks).","Relacorilant NDA for Cushing's under FDA review with PDUFA Dec 30, 2025; NDA for ovarian cancer expected Q3 2025.","Phase 3 ROSELLA trial met PFS and OS endpoints; results to be presented at ASCO June 2025.","Dazucorilant ALS trial missed primary endpoint; exploratory survival benefit at 1yr (HR 0.16, p=0.0009); seeking regulatory input."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-022167","json":"https://secwatch.observer/filing/0001628280-25-022167.json","markdown":"https://secwatch.observer/filing/0001628280-25-022167.md","text":"https://secwatch.observer/filing/0001628280-25-022167.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1088856/000162828025022167/0001628280-25-022167-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1088856/000162828025022167/cort-20250505.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T16:23:34.144339+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}